CNSide Diagnostics

10/13/2026

Last week, the CNSide team hit an extraordinary milestone: 10 patient kits received in one day! This incredible news combined with the official launch of the NGS-based Molecular Profile tests is a testament to our dedicated laboratory team’s tireless work.

Learn more about how CNSide is redefining CNS tumor management: bit.ly/4jL20f1

Cerenome

10/06/2026

CNSide now offers more ways to potentially gain insights from cerebrospinal fluid.

Starting October 12, physicians in the U.S. can order the following CNSide® CSF Molecular Profile tests:

- CNSide® CSF Molecular Profile - Solid Tumor (DNA & RNA)
- CNSide® CSF Molecular Profile - Hematologic Malignancies (DNA & RNA)

Molecular Profile looks at more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions; in addition, the Hematologic Malignancies test supports molecular assessment of clonality.

The tests also take CNSide beyond leptomeningeal metastases (LM) and can be used for primary CNS tumors, solid tumors that have spread to the CNS, and hematologic cancers involving the CNS.

For patients with suspected or confirmed LM, Molecular Profile can also be ordered alongside CNSide® CSF TCE (Tumor Cell Enumeration) when clinically appropriate.

Learn more and order at https://hubs.la/Q04zf9Xr0

10/01/2026

Diagnosing LM can be challenging when conventional findings are inconclusive.

A retrospective, single-institution analysis that evaluated 12 patients with suspected LM comparing CNSide® CSF TCE and NGS with standard MRI and CSF cytology and using a cutoff of >0 CSF tumor cells/mL, CNSide demonstrated:

- 77.8% sensitivity
- 100% specificity
- 100% positive predictive value
- 88.3% accuracy

CNSide detected CSF tumor cells in 7 of 12 patients, supporting the potential role of CSF tumor cell quantification as a complementary tool to MRI and CSF cytology when evaluating suspected LM.

The study also highlights the potential of integrating CSF tumor cell analysis with NGS to provide additional molecular insights in patients with CNS-involved metastatic disease.

Read the snapshot of the peer-reviewed study by Onoichenco et al. in Neuro-Oncology Advances: https://hubs.la/Q04yQQQm0

Source: Onoichenco et al. Neuro-Oncology Advances. 2026

09/22/2026

CNSide Diagnostics has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan for the CNSide® CSF Tumor Cell Enumeration assay, effective September 1, 2026. BCBSM serves approximately 5 million commercial and Medicare Advantage members.

CNSide® now holds contracted reimbursement coverage representing approximately 158 million covered lives nationwide.

This achievement is part of our ongoing commitment to:
- Expanding patient access to innovative diagnostics
- Supporting clinicians with actionable diagnostic insights
- Advancing options for the LM community

For your patients with suspected or confirmed leptomeningeal metastases, that means one fewer barrier between a clinical question and a quantitative CSF answer.

Read more in our Press Release: https://hubs.la/Q04y0lx20

09/17/2026

For patients with LM, tracking disease over time can be challenging. However, serial CSF monitoring may provide additional insight into disease burden and treatment response.

In a case of a rare, aggressive CNS tumor with leptomeningeal dissemination, serial CNSide® CSF TCE tests provided longitudinal insight across 7 time points, all while CSF cytology and routine CSF parameters remained unremarkable.

This study by Pelletier et al. demonstrates the potential of serial CSF tumor cell monitoring to provide a complementary view of disease burden and treatment response during complex, multimodal therapy.

For physicians managing patients with LM, more data from the CSF may offer another perspective when tracking what’s happening below the surface.

Read the snapshot of the case study by Pelletier et al. in Cureus: https://hubs.la/Q04xMLqY0

Source: Pelletier et. al. Cureus 18(2): e103982

09/10/2026

What molecular story is the CNS telling?

This clinical data highlight is from a prospective UCSF study of patients with metastatic breast cancer and leptomeningeal metastases (LM) and shows why looking directly at the CSF matters.

- 50% of patients with confirmed LM had molecular alterations detected by CSF NGS
- 71.4% of tested patients had CSF tumor cells detected by CNSide®

CSF and extracranial NGS showed variable concordance and discordance, highlighting the potential for CNS-specific molecular insights that may not be captured outside the CNS. CNSide identified tumor cells and pathogenic/actionable mutations in patients with negative CSF cytology.

Read the snapshot of the peer-reviewed study by Huppert et al. in Therapeutic Advances in Medical Oncology: https://hubs.la/Q04x5DRB0

Source: Huppert et al. Ther Adv Med Oncol. 2026;18:17588359261424678.

09/09/2026

What if we stopped managing leptomeningeal metastases the way we always have?

The future of LM care will require more than traditional diagnostics. It will require better data, deeper molecular insight, and a more precise understanding of what’s happening in the CNS.

At our recent symposium at the SNO/ASCO CNS Metastases Conference, leading experts in neuro-oncology explored what that future could look like from CSF-based diagnostics and molecular profiling to AI, data analytics, and emerging therapies.

The conversation is changing. Is your approach keeping up?

Watch the full symposium recording, NOW AVAILABLE ON OUR YOUTUBE: https://hubs.la/Q04w_58D0

08/05/2026

Join us at the 2026 SNO/ASCO CNS Metastases Conference for an important discussion on the evolving management of leptomeningeal metastases.

CNSide Diagnostics and Cerenome (formerly Plus Therapeutics) are proud to sponsor the symposium:
Redefining the Management of Leptomeningeal Metastases: Integrating Diagnostics, Molecular Insights, and Emerging Therapies

This expert-led session will explore how advances in CSF diagnostics, molecular insights, and emerging therapies are helping shape the future of LM management.

> Attending SNO/ASCO?
Pre-register today to reserve your spot: https://hubs.la/Q04rVVxt0
> Can't attend in person?
Request a recording and watch the symposium on demand after the event: https://hubs.la/Q04rVVxt0

Learn more about our scientific presentations at the conference next week: https://hubs.la/Q04rW5rv0

07/21/2026

Medical Mutual has signed a regional coverage agreement for the CNSide® CSF Tumor Cell Enumeration (TCE) assay, providing access to approximately 1.2 million covered lives across Ohio and Kentucky and increasing CNSide's total contracted coverage to approximately 127 million people.

CNSide supports rapid diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases, helping clinicians make more informed decisions when every moment matters.

As we continue expanding patient access nationwide, we're committed to advancing precision diagnostics for patients with metastatic CNS cancer.

Learn more: https://hubs.la/Q04q1mWc0

07/16/2026

We're excited to share that CNSide is expanding its capabilities through a new collaboration with Genomic Testing Cooperative to integrate next-generation sequencing (NGS) into the CNSide® CSF assay platform.

By combining guideline-recognized circulating tumor cell (CTC) enumeration with comprehensive DNA and RNA profiling from a single CSF specimen, this collaboration is designed to provide clinicians with a more comprehensive molecular view to help inform patient management and research.

This milestone reflects our continued commitment to advancing precision diagnostics and supporting better clinical insights for patients with CNS cancers.

Read the full announcement below.

About CNSide: cnside-dx.com/?utm=source_social

announces a collaboration to integrate Genomic Testing Cooperative's next-generation sequencing (NGS) technology into the CNSide Diagnostics' cerebrospinal fluid (CSF) assay platform.

The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending from guideline-recognized CTC enumeration into the guideline-recognized DNA and tumor-derived DNA analytic layer within one integrated platform.

The collaboration advances ’s three-pillar CNS strategy:
- Targeted led by ™ (rhenium Re186 obisbemeda)
- Precision diagnostics anchored by the CNSide CSF platform
- -enabled data analytics through the Company’s strategic
partnership with @‌Ephemeral Technologies

Full press release here: bit.ly/4vuCU6f